Zacks Research Issues Pessimistic Forecast for HALO Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Stock analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, down […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Stock analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for Halozyme Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, down […]
